Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Gene Therapy00:59

Gene Therapy

26.4K
Gene therapy is a technique where a gene is inserted into a person’s cells to prevent or treat a serious disease. The added gene may be a healthy version of the gene that is mutated in the patient, or it could be a different gene that inactivates or compensates for the patient’s disease-causing gene. For example, in patients with severe combined immunodeficiency (SCID) due to a mutation in the gene for the enzyme adenosine deaminase, a functioning version of the gene can be...
26.4K
The Retinoblastoma Gene01:20

The Retinoblastoma Gene

4.3K
Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
4.3K
What is Genetic Engineering?00:49

What is Genetic Engineering?

76.6K
Overview
76.6K
iPS Cell Differentiation01:22

iPS Cell Differentiation

2.9K
The ability of induced pluripotent stem cells or iPSCs to differentiate into most body cell types has stimulated repair and regenerative medicine research over the past few decades. iPSC-derived blood cells, hepatocytes, beta islet cells, cardiomyocytes, neurons, and other cell types can repair injuries or regenerate damaged tissue in diseases such as diabetes and neurodegenerative disorders.
2.9K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[DNA informs on ancient partner choice].

Medecine sciences : M/S·2026
Same author

[TimeVaults provide recordings of past cellular activity].

Medecine sciences : M/S·2026
Same author

[In vivo CAR-Ts, a significant breakthrough].

Medecine sciences : M/S·2026
Same author

[House of cards?]

Medecine sciences : M/S·2026
Same author

[Towards gene therapy for Hutington's disease].

Medecine sciences : M/S·2025
Same author

[DNA reveals the living world].

Medecine sciences : M/S·2025

Related Experiment Video

Updated: Nov 7, 2025

Preparation and Gene Modification of Nonhuman Primate Hematopoietic Stem and Progenitor Cells
11:16

Preparation and Gene Modification of Nonhuman Primate Hematopoietic Stem and Progenitor Cells

Published on: February 15, 2019

7.8K

[Towards gene therapy for Progeria ?]

Bertrand Jordan1

  • 1UMR 7268 ADÉS, Aix-Marseille, Université /EFS/CNRS ; CoReBio PACA, case 901, Parc scientifique de Luminy, 13288 Marseille Cedex 09, France.

Medecine Sciences : M/S
|April 28, 2021
PubMed
Summary
This summary is machine-generated.

Gene editing successfully reversed Hutchinson-Gilford Progeria symptoms in cell and mouse models. This breakthrough in base editing offers hope for treating premature aging diseases.

More Related Videos

Electroporation-Based Genetic Modification of Primary Human Pigment Epithelial Cells Using the Sleeping Beauty Transposon System
07:04

Electroporation-Based Genetic Modification of Primary Human Pigment Epithelial Cells Using the Sleeping Beauty Transposon System

Published on: February 4, 2021

2.2K
Conditional Reprogramming of Pediatric Human Esophageal Epithelial Cells for Use in Tissue Engineering and Disease Investigation
10:15

Conditional Reprogramming of Pediatric Human Esophageal Epithelial Cells for Use in Tissue Engineering and Disease Investigation

Published on: March 22, 2017

7.1K

Related Experiment Videos

Last Updated: Nov 7, 2025

Preparation and Gene Modification of Nonhuman Primate Hematopoietic Stem and Progenitor Cells
11:16

Preparation and Gene Modification of Nonhuman Primate Hematopoietic Stem and Progenitor Cells

Published on: February 15, 2019

7.8K
Electroporation-Based Genetic Modification of Primary Human Pigment Epithelial Cells Using the Sleeping Beauty Transposon System
07:04

Electroporation-Based Genetic Modification of Primary Human Pigment Epithelial Cells Using the Sleeping Beauty Transposon System

Published on: February 4, 2021

2.2K
Conditional Reprogramming of Pediatric Human Esophageal Epithelial Cells for Use in Tissue Engineering and Disease Investigation
10:15

Conditional Reprogramming of Pediatric Human Esophageal Epithelial Cells for Use in Tissue Engineering and Disease Investigation

Published on: March 22, 2017

7.1K

Area of Science:

  • Molecular Biology
  • Genetics
  • Medical Science

Background:

  • Hutchinson-Gilford Progeria (HGP) is a rare, fatal genetic disorder characterized by premature aging.
  • HGP is caused by a specific point mutation in the lamin A gene, leading to the production of a toxic protein.
  • Current treatments for HGP are largely supportive, focusing on managing symptoms.

Discussion:

  • Recent advancements in base editing technology have enabled precise correction of the HGP-causing mutation.
  • Studies demonstrated successful correction in patient-derived cell lines and a relevant mouse model.
  • The correction resulted in a near-complete phenotypic reversal, restoring normal cellular function.

Key Insights:

  • Base editing offers a potential therapeutic strategy for Hutchinson-Gilford Progeria.
  • Precise correction of the lamin A gene mutation can reverse the disease phenotype.
  • This approach validates gene editing as a viable treatment for genetic disorders.

Outlook:

  • The success in preclinical models paves the way for potential clinical applications in HGP.
  • Further research is needed to assess long-term efficacy and safety for human trials.
  • This gene editing strategy may be adaptable for treating other genetic diseases caused by point mutations.